The Supreme Court says generic drug manufacturers can't be sued in state court for a drug's design defects if federal officials approved the brand-name version the generic drug copied.
The Supreme Court says generic drug manufacturers can’t be sued in state court for a drug’s design defects if federal officials approved the brand-name version the generic drug copied.
The justices voted 5-4 to agree with generic manufacturer Mutual Pharmaceutical Co, Inc., which wanted a $21 million judgment against it dismissed.
A New Hampshire jury gave that to Karen L. Bartlett after she took sulindac, the generic form of the drug Clinoril, in 2004. It caused her outer skin layer to deteriorate and burn off, leaving at least 60 percent of her body as an open wound. She is also now legally blind.
The federal appeals courts upheld her verdict, but the justices said federal law pre-empts the New Hampshire law that allowed Bartlett’s lawsuit.
- Capitol Hill light-rail station nearly ready for trains to rumble
- Marymoor Park concerts: Full lineup announced
- Nelson Cruz's home run in ninth inning lifts Mariners to sweep of Rays
- Historically black Central District could be less than 10% black in a decade
- Kyle Seager saves Mariners, 7-6, in 10 innings